ORYZF Stock Chart & Stats
$3.34
$0.05(1.45%)
At close: 4:00 PM EDT
$3.34
$0.05(1.45%)
Day’s Range― - ―
52-Week Range$2.85 - $4.38
Previous CloseN/A
Volume500.00
Average Volume (3M)1.42K
Market Cap
$265.79M
Enterprise Value$230.85
Total Cash (Recent Filing)$22.12M
Total Debt (Recent Filing)$7.10M
Price to Earnings (P/E)―
Beta0.32
Next Earnings
Oct 22, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding84,332,150
10 Day Avg. Volume2,050
30 Day Avg. Volume1,420
Financial Highlights & Ratios
PEG Ratio2.31
Price to Book (P/B)2.19
Price to Sales (P/S)0.00
P/FCF Ratio-95.74
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$11.97Price Target Upside258.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.12
Revenue Forecast (FY)$8.38M
Bulls Say, Bears Say
Bulls Say
Proprietary Epigenetics PipelineA proprietary small-molecule platform focused on epigenetic targets gives Oryzon multiple opportunities across oncology and CNS indications. Successful clinical progress could support licensing, partnerships, and future commercialization beyond a single program.
Supportive Balance SheetModest leverage and a growing equity base provide more financial flexibility than many development-stage biotechs. This can help sustain research activity and absorb volatility while programs advance toward potential value-creating milestones.
Licensing UpsideA licensing-based model can provide non-dilutive or partially offsetting funding if pipeline assets attract partners. Upfront payments, milestones, and royalties may diversify future financing sources and extend development capacity.
Bears Say
Persistent UnprofitabilityOngoing operating and net losses show that the company has not yet converted research investment into commercial earnings. Until a candidate is approved or partnered on attractive terms, profitability remains dependent on external funding and pipeline execution.
Unreliable Revenue BaseRepeated zero-revenue years make the business difficult to underwrite and indicate dependence on irregular licensing or collaboration income. Without recurring product sales, financial performance may remain highly volatile until regulatory approval or durable partnerships emerge.
Continued Cash BurnPersistent negative operating and free cash flow means development activities are not self-funded. Even with improvement in 2025, continued cash burn can require additional capital, creating dilution risk and limiting flexibility if financing conditions weaken.
Oryzon Genomics SA News
ORYZF FAQ
What was Oryzon Genomics SA’s price range in the past 12 months?
Oryzon Genomics SA lowest stock price was $2.85 and its highest was $4.38 in the past 12 months.
What is Oryzon Genomics SA’s market cap?
Oryzon Genomics SA’s market cap is $265.79M.
When is Oryzon Genomics SA’s upcoming earnings report date?
Oryzon Genomics SA’s upcoming earnings report date is Oct 22, 2026 which is in 42 days.
How were Oryzon Genomics SA’s earnings last quarter?
Oryzon Genomics SA released its earnings results on Jul 27, 2026. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.065 by $0.065.
Is Oryzon Genomics SA overvalued?
According to Wall Street analysts Oryzon Genomics SA’s price is currently Undervalued.
Does Oryzon Genomics SA pay dividends?
Oryzon Genomics SA does not currently pay dividends.
What is Oryzon Genomics SA’s EPS estimate?
Oryzon Genomics SA’s EPS estimate is -0.08.
How many shares outstanding does Oryzon Genomics SA have?
Oryzon Genomics SA has 84,332,150 shares outstanding.
What happened to Oryzon Genomics SA’s price movement after its last earnings report?
Oryzon Genomics SA reported an EPS of $0 in its last earnings report, beating expectations of -$0.065. Following the earnings report the stock price went up 0.291%.
Which hedge fund is a major shareholder of Oryzon Genomics SA?
Currently, no hedge funds are holding shares in ORYZF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oryzon Genomics SA
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases; and ORY-4001, a selective HDAC-6 inhibitor for the treatment of neurological disorders, such as Charcot-Marie-Tooth disease (CMT), amyotrophic lateral sclerosis (ALS), and others. It also has collaborations in precision medicine with Columbia University in New York and the Institute of Medical and Molecular Genetics (INGEMM) at La Paz Hospital in Madrid psychometrically characterize patients with mutations in the SetD1A or Shank3 genes; and Cooperative Research and Development Agreement (CRADA) to sponsor several clinical trials. The company was incorporated in 2000 and is based in Cornellà de Llobregat, Spain.
ORYZF Stock 12 Month Forecast
Average Price Target
$11.97
▲(258.32% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.09% Mutual Funds
― Other Institutional Investors
99.82% Public Companies and
Individual Investors